Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05139680 · ClinicalTrials.gov registry record
A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 10
- Enrollment target
NCT05139680 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 10 participants.
The verdict
NCT05139680 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Hereditary Transthyretin Amyloidosis using data that already exist in patients' medical records.
Interventions
- DRUG tafamidis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2023-05-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05139680
The ClinicalTrials.gov registry entry for NCT05139680 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tafamidis is the first listed.
NCT05139680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05139680 about?
NCT05139680 is a clinical study titled "A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis". This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Hereditary Transthyretin Amyloidosis using data that already exist in patients' medical records.
What is the current status of trial NCT05139680?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2023-03-08. Estimated completion is 2023-05-19.
What interventions are being tested in trial NCT05139680?
The interventions under investigation include: tafamidis (DRUG).
Who is sponsoring clinical trial NCT05139680?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.